@article{b155549453b94b41a5c8c275640541c3,
title = "Focal hemosiderin deposits and β-amyloid load in the ADNI cohort",
abstract = "Background: Prevalence and risk factors for focal hemosiderin deposits are important considerations when planning amyloid-modifying trials for treatment and prevention of Alzheimer's disease (AD). Methods: Subjects were cognitively normal (n = 171), early-mild cognitive impairment (MCI) (n = 240), late-MCI (n = 111), and AD (n = 40) from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Microhemorrhages and superficial siderosis were assessed at baseline and on all available MRIs at 3, 6, and 12 months. β-amyloid load was assessed with 18F-florbetapir positron emission tomography. Results: Prevalence of superficial siderosis was 1% and prevalence of microhemorrhages was 25% increasing with age (P <.001) and β-amyloid load (P <.001). Topographic densities of microhemorrhages were highest in the occipital lobes and lowest in the deep/infratentorial regions. A greater number of microhemorrhages at baseline was associated with a greater annualized rate of additional microhemorrhages by last follow-up (rank correlation = 0.49; P <.001). Conclusions: Focal hemosiderin deposits are relatively common in the ADNI cohort and are associated with β-amyloid load.",
keywords = "ADNI, Alzheimer's disease, Amyloid, Early mild cognitive impairment, Florbetapir, MRI, Microhemorrhage, Mild cognitive impairment, PET, Superficial siderosis",
author = "Kejal Kantarci and Gunter, {Jeffrey L.} and Nirubol Tosakulwong and Weigand, {Stephen D.} and Senjem, {Matthew S.} and Petersen, {Ronald C.} and Aisen, {Paul S.} and Jagust, {William J.} and Weiner, {Michael W.} and Jack, {Clifford R.}",
note = "Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129 and K01 AG030514. Investigator efforts and data analysis for this study is funded by R01 AG40042 to KK and R01 AG11378 to CRJ. The authors thank Samantha Wille for her help with manuscript formatting and submission. ",
year = "2013",
month = oct,
doi = "10.1016/j.jalz.2012.10.011",
language = "English (US)",
volume = "9",
pages = "S116--S123",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "5 SUPPL.",
}